Navigation Links
Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
Date:9/27/2010

SAN DIEGO, Sept. 27 /PRNewswire-FirstCall/ -- Amira Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for AM152, a novel LPA1 antagonist.  If accepted, the IND will enable Amira to begin Phase 1 safety studies with the compound in healthy subjects.

"We believe the pre-clinical data obtained to date for AM152 demonstrate characteristics which warrant further studies in humans to determine its potential utility in various fibrotic diseases," said Isabelle DeArmond, Vice President, Clinical Development. "The safety and pharmacokinetic data obtained from Phase 1 studies are an important first step in the clinical investigation of this program."

Added Bob Baltera, Chief Executive Officer, "We are extremely excited to reach this point with our LPA1 program. There have recently been numerous papers published describing the novel biology of the LPA1 receptor and how it relates to abnormal fibrotic processes.  We have worked hard to develop this program and look forward to learning more about this potential therapeutic candidate in a clinical setting."

While there are no LPA1 selective antagonists approved for therapeutic use, there is a strong scientific rationale for this target to be a novel treatment in various fibrotic diseases, including scleroderma and idiopathic pulmonary fibrosis.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-li
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
2. Visage Imaging Releases Amira 5.3
3. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
4. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
5. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
6. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
7. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
8. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
9. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
10. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
11. Lotus Pharmaceuticals Announces Two Senior Management Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 IGI Laboratories, ... based specialty generic pharmaceutical company, today announced ... its Board of Directors.  Mr. Finio has accepted a ... under the terms of his acceptance of his new ... his role as Director for IGI Laboratories, Inc.  The ...
(Date:7/24/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, today ... fiscal year 2014 financial results after the market close ... will follow on the same day at 4:30 p.m. ... hosted by Dan Myers , President and Chief ...
(Date:7/24/2014)... KIRKLAND, Wash. , July 24, 2014 ... exhibiting at the 2014 National Association of State Veterans ... Carolina . The goal of the NASVH is ... receives the benefits, services, long term health care and ... sacrifice. With the InSite® Remote Dispensing ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Alimera Sciences To Release Second Quarter 2014 Results 2Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2
... 2011 Stereotaxis, Inc. (NASDAQ: STXS ) today ... conferences during May 2011: The Deutsche Bank ... and Chief Executive Officer of Stereotaxis, is scheduled to present ... at 4:10 p.m. ET. The JMP Securities Annual Research ...
... Pharmasset, Inc. (Nasdaq: VRUS ), a clinical ... novel drugs to treat viral infections, today reported financial ... 31, 2011. Financial ResultsRevenues were ... compared to $0.3 million for the quarter ended March ...
Cached Medicine Technology:Stereotaxis to Present at Upcoming Investor Conferences 2Stereotaxis to Present at Upcoming Investor Conferences 3Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2011 Financial Results 5
(Date:7/24/2014)... MEMPHIS, Tenn. Researchers at Le Bonheur Children,s Hospital ... results of a clinical trial of a new drug ... illness of healthy adult volunteers intranasally infected with respiratory ... of lower respiratory tract infections in young children in ... comes from the labs of Infectious Disease Specialist John ...
(Date:7/24/2014)... 24, 2014 In signing the ... Obama cited the Atlanta BeltLine Workforce Partnership in ... across the country ( http://www.whitehouse.gov/ready-to-work ). The ... pillar of U.S. economic strategy and profiled successful ... recognition from President Obama highlights the power of ...
(Date:7/24/2014)... with high-throughput data generated by breast cancer biologists ... computational method to determine how gene networks are ... as they respond to potential cancer therapy agents., ... each other in laboratory-grown cells is described in ... PLOS Computational Biology . , The method ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... E. Taylor, M.D., director of The Miriam Hospital,s ... 2014 Rhode Island Medical Journal special ... c virus infection (hep c or HCV) is ... address other health challenges, and improve health care ... States, Taylor says, include lack of funding earmarked ...
Breaking Medicine News(10 mins):Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... Children who can read and have good phonetic skills - ... may still be poor spellers. In a paper published in ... Annett, at the School of Psychology of Leicester, UK, show ... be right-handed than other poor spellers. , The three-year study ...
... May 29 Alsius Corporation,(Nasdaq: ALUS ... (IVTM(TM)) therapies for critically ill patients, was ... L.P. to provide,intravascular temperature management products to ... the fifth contract we have been awarded ...
... to what is known about relationship between fitness and,diabetes, ... 2 diabetes in women is significantly increased as a ... Index (BMI), and a,combination of the two increases the ... at the 55th Annual Meeting of the American,College of ...
... a first for URAC, the,independent, non-profit accreditation organization ... has developed to help case management,practitioners assess patient ... instrument is a standardized assessment case managers,can voluntarily ... from any interested,parties, including purchasers, policy makers, consumers, ...
... that they have coordinated all the entertainment for Rhinestone ... Hotel Indigo, on,West End, from 7pm until midnight., ... a,place for you to connect with artists, friends and ... the world of country music quick, easy,and free!, ...
... firefighters study to be presented at ... American College of Sports Medicine, MISSOULA, ... Exercise Metabolism (Montana WPEM) will present a human,clinical study at ... that wildland firefighters who consumed a yeast based,(beta glucan) antioxidant ...
Cached Medicine News:Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 2Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 2Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 3Health News:Studies Define Type 2 Diabetes Risk Factors in Women, Adolescents 4Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 2Health News:URAC Develops New Case Management Patient Satisfaction Tool, Invites Public Input On Voluntary Survey Instrument 3Health News:DigitalRodeo.com Lines Up Entertainment for Rhinestone Cure 2Health News:Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study 2
Intended for the quantitative determination of direct bilirubin in serum. Modified EvelynMalloy Method. Endpoint Reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... Powerwave is the first microplate spectrophotometer ... day, 7 days per week. With rugged ... footprint. Powerwave breaks the barrier of traditional ... reliably. One instrument can easily read up ...
Spectra 3000RS & Spectra 3000RSP are very precise instruments. They have a metal base structure, durable parts for long life use, and they are very easy to use and maintain....
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
Medicine Products: